Dustri Online Services

Books: 0	Journals: 2	Articles: 10

Abstract

International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 12/2013 (986-988)

Lower metabolic clearance of tizanidine in Japanese subjects

Kenji Momo, Masato Homma and Yukinao Kohda

Department of Pharmaceutical Sciences, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
Our aim was to determine whether metabolic clearance, renal clearance, or both elimination pathways contribute to ethnic differences in tizanidine clearance, which is ~ 2-fold higher in Caucasians than in Asians. The pharmacokinetic parameters of tizanidine in 9 healthy male Japanese subjects were compared with those of Caucasians in previous studies. Metabolic clearance of tizanidine was lower in Japanese than in Caucasian subjects (5.9 vs. 8.1 – 10.9 l/h/kg), although renal clearances were similar (0.040 vs. 0.047 – 0.055 l/h/kg). The results suggest that ethnic differences in tizanidine clearance are due to differences in metabolic clearance.Correspondence to:
Dr. Masato Homma
Department of Pharmaceutical Sciences
Faculty of Medicine, University of Tsukuba
Tennodai 1-1-1, Tsukuba, Ibaraki 305-8575, Japan
Email: [email protected]

Abstract

Clinical Nephrology, Vol. 91 – No. 6/2019 – Letters to the editor

Acute kidney injury incidence in patients with hematological malignancy treated with meropenem and vancomycin for febrile neutropenia

Shunsuke Kobayashi, Takeo Yasu, and Kenji Momo

Department of Pharmacy, The Institute of Medical Science Hospital, The University of Tokyo, Tokyo, Japan
Correspondence to:
Shunsuke Kobayashi, MSc
Department of Pharmacy
The Institute of Medical Science Hospital
The University of Tokyo
4-6-1, Shirokanedai, Minato-ku,
Tokyo, 108-8639, Japan
Email: [email protected]

Abstract

Clinical Nephrology, Vol. 92 – No. 2/2019 – Letters to the editor

AKI in patients with hematological malignancies treated with various vancomycin-antibiotic combinations

Shunsuke Kobayashi¹#²*, Takeo Yasu¹#³*, and Kenji Momo¹#⁴

¹Department of Pharmacy, The Institute of Medical Science Hospital, The University of Tokyo, ²Department of Pharmacy, Nissan Tamagawa Hospital, ³Department of Medicinal Therapy Research, Meiji Pharmaceutical University, and ⁴Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, Tokyo, Japan

*Contributed equally
Correspondence to:
Shunsuke Kobayashi, MSc
Department of Pharmacy, Nissan Tamagawa Hospital
4-8-1, Seta, Setagaya-ku, Tokyo,158-0095, Japan
Email: [email protected]

Abstract

International Journal of Clinical Pharmacology and Therapeutics, Vol. 57 – No. 8/2019 (416-419)

Thiamine deficiency as a possible cofactor causing cognitive dysfunction in a patient with end-stage gastric cancer 

Yohei Iimura¹, Takeo Yasu¹#², Kenji Momo¹#³, Seiichiro Kuroda¹, Yoshiaki Kanemoto⁴, Kentaro Yazawa⁴, and Giichiro Tsurita⁴

¹Department of Pharmacy, Research Hospital, ²Department of Medicinal Therapy Research, Meiji Pharmaceutical University, ³Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, and ⁴Department of Surgery, IMSUT Hospital, Institute of Medical Science, University of Tokyo, Tokyo, Japan
We describe a case of a patient treated for cognitive dysfunction (CD) with suspected thiamine deficiency (TD). A 74-year-old man with gastric cancer presented with grade 3 diarrhea and grade 1 anorexia. He had been receiving trastuzumab plus tegafur (a chemotherapeutic fluorouracil prodrug), gimeracil, and oteracil (S-1) and oxaliplatin. On admission, cognitive function was assessed with the Hasegawa’s Dementia Scale (HDS-R) because he had impaired short-term memory. His thiamine levels increased from 22 to 109 ng/mL after administration of 75 mg of thiamine. Furthermore, the patient’s HDS-R score improved from 9 to 22, and cognitive and memory functions improved. TD should be considered in older CD patients receiving oral chemotherapy agents including fluorouracil.Correspondence to:
 Yohei Iimura, Bsc. 
Department of Pharmacy, The Research Hospital
The Institute  of Medical Science
The University of Tokyo
4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan
Email: [email protected]

Abstract

International Journal of Clinical Pharmacology and Therapeutics, Vol. 58 – No. 3/2020 (174-176)

Potential thiamine deficiency in elderly patients with gastrointestinal cancer undergoing chemotherapy 

Takeo Yasu¹#², Yohei Iimura¹, Kenji Momo¹#³, and Seiichiro Kuroda¹

¹Department of Pharmacy, The Research Hospital, The Institute of Medical Science, The University of Tokyo, ²Department of Medicinal Therapy Research, Meiji Pharmaceutical University, and ³Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, Tokyo, Japan
Gastrointestinal cancer and its treatment using fluorouracil-based anticancer agents are risk factors for thiamine deficiency (TD). Therefore, we aimed to determine the prevalence of TD among elderly patients with gastrointestinal cancer undergoing chemotherapy. We retrospectively reviewed the medical records of 12 elderly patients with gastrointestinal cancers who underwent chemotherapy. Median serum thiamine level was 22.5 ng/mL (range, 17 – 42 ng/mL). Four patients (33.3%) exhibited TD (< 20 ng/mL). We found that the prevalence of TD among elderly patients with gastrointestinal cancer undergoing chemotherapy was high. For these patients, careful monitoring of thiamine levels is warranted because TD may not produce overt clinical symptoms.Correspondence to:
 Takeo Yasu, PhD 
Department of Medicinal Therapy Research
Meiji Pharmaceutical University
2-522-1 Noshio, Kiyose, Tokyo, 204-8588, Japan
Email: yasutakeo-tky@ umin.ac.jp

Abstract

Intern. Journal of Clinical Pharmacology and Therapeutics, Vol. 60 – No. 8/2022 – Letter to the editor

Drug-drug interaction between apalutamide and atorvastatin through breast cancer resistance protein in an outpatient

Ayako Watanabe¹#², Kenji Momo², Katsumi Tanaka¹#², Masaki Kida¹#², Remi Kuchira¹#², Hiromi Koshizuka¹#², Kota Nishimura³, Masashi Morita³, Masahiro Yamamoto⁴, and Tadanori Sasaki⁵

¹Department of Pharmacy, Showa University Koto Toyosu Hospital, ²Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, ³Department of Urology, Showa University Koto Toyosu Hospital, ⁴Department of Nephrology, Showa University Koto Toyosu Hospital, and ⁵Department of Pharmacy, Showa University Hospital, Tokyo, Japan
Correspondence to:
Associate Prof. Kenji Momo, PhD
Department of Hospital Pharmaceutics
School of Pharmacy, Showa University
Hatanodai 1-5-8, Shinagawa-ku
Tokyo 142-8555, Japan
Email: [email protected]

Abstract

International Journal of Clinical Pharmacology and Therapeutics, Vol. 62 – No. 11/2024 (538-542)

A case of a geriatric patient with thrombocytopenia after partial recovery from COVID-19 

Yukako Hayashi¹#², Kenji Momo², Mutsumi Ando¹#², Hiroaki Koya¹#², Tsutomu Nagai¹#², Kazuki Shinmura³#⁴, Issei Tokimatsu⁵, Yasushi Akutsu⁶#⁷, and Masahiro Kurosawa¹#²

¹Department of Pharmacy, Showa University Karasuyama Hospital, ²Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, ³Department of Psychiatry, School of Medicine, Showa University, ⁴Department of Psychiatry, Showa University Karasuyama Hospital, ⁵Department of Medicine, Division of Clinical Infectious Diseases, School of Medicine, Showa University, ⁶Division of Cardiology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, and ⁷Department of Internal Medicine, Showa University Karasuyama Hospital, Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan
The global emergence of COVID-19 has prompted rapid therapeutic and vaccine advancements; however, clinical evidence remains limited. With around a 50% fatality rate for COVID-19 patients with acute respiratory distress syndrome (ARDS), early intervention is crucial. This report details a severe case of post-COVID-19 thrombocytopenia in a 79-year-old man and emphasizes its critical nature. Despite negative initial COVID-19 test results, subsequent positive results led to treatment initiation, and severe thrombocytopenia persisted resulting in bleeding complications and death. Recognized as a hematological manifestation of COVID-19, thrombocytopenia in this geriatric patient highlights the need for extended post-COVID-19 monitoring and management. This underscores the importance of vigilance and timely intervention, especially in vulnerable populations, and emphasizes the need for further research to understand the intricate relationship between COVID-19 and thrombocytopenia.Correspondence to:
Associate Prof. Kenji Momo, PhD
Department of Hospital Pharmaceutics
School of Pharmacy, Showa University
Hatanodai 1-5-8, Shinagawa-ku, Tokyo 142-8555, Japan
Email: [email protected]

Abstract

International Journal of Clinical Pharmacology and Therapeutics, Vol. 63 – No. 7/2025 (309-317)

Simultaneous determination of cefmetazole and cefaclor in urine from pediatric patients with urinary tract infections using a newly developed high-performance liquid chromatography assay method 

Erika Maeda¹#², Kurumi Abe¹#², Izumi Takayama²#³, Haruka Sawai², Takeru Kanazawa⁴, Ryo Karato⁴, Yoshifusa Abe⁴, and Kenji Momo²

¹Department of Pharmacy, Showa Medical University Koto Toyosu Hospital, ²Department of Hospital Pharmaceutics, School of Pharmacy, Showa Medical University, ³Department of Pharmacy, Showa Medical University Hospital, and ⁴Children’s Medical Center, Showa Medical University Koto Toyosu Hospital, Tokyo, Japan
Background: A simple and rapid assay method is urgently required in clinical settings to monitor the efficacy and safety of antibiotics in pediatric patients with urinary tract infection (UTI).
Aims: To develop a cost-effective high-performance liquid chromatography-ultraviolet (HPLC-UV) method to simultaneously determine cefaclor and cefmetazole concentrations in the urine of pediatric patients with UTI.
Materials and methods: Calibration curves were used to validate the linear ranges of cefaclor (31.25 – 500 µg/mL) and cefmetazole (62.5 – 1,000 µg/mL).
Results: The developed method showed satisfactory precision: intra-day coefficients of variations (CV) 1.1 – 7.6% and inter-day CV of 3.7 – 13.8% for cefaclor, and intra-day CV of 0.5 – 5.9% and inter-day CV of 4.5 – 13.2% for cefmetazole. The validity of the method was confirmed using urine bag samples from infants with UTI. The urinary concentrations of cefaclor and cefmetazole in infants with UTI were 313.5 μg/mL and 1,572.5 μg/mL, respectively.
Conclusion: We developed and validated an HPLC-UV method for the simultaneous measurement of cefaclor and cefmetazole in pediatric patients with UTI. The assay is rapid, cost-effective, and suitable for therapeutic drug monitoring.Correspondence to:
Associate Prof. Kenji Momo, PhD
Division of Clinical Research
Department of Hospital Pharmaceutics
School of Pharmacy, Showa Medical University
Hatanodai 1-5-8, Shinagawa-ku,
Tokyo 142-8555, Japan
Email: [email protected]

Abstract

International Journal of Clinical Pharmacology and Therapeutics, Vol. 64 – No. 8/2026 (398-406)

Timing of antimicrobial stewardship intervention and mortality among patients admitted to intensive care unit s

Akitoshi Takuma¹#², Airi Miura²#³, Kotono Tagami², and Kenji Momo⁴

¹Department of Pharmacy, Showa Medical University Northern Yokohama Hospital, Tsuzuki-ku, Yokohama, Kanagawa, ²Division of Hospital Pharmaceutics, Department of Hospital Pharmaceutics, School of Pharmacy, Showa Medical University, Shinagawa-ku, ³Department of Pharmacy, Kanagawa Rehabilitation Hospital, Kanagawa Rehabilitation Center, Atsugi-shi, Kanagawa, and ⁴Division of Clinical Research, Department of Hospital Pharmaceutics, School of Pharmacy, Showa Medical University, Shinagawa-ku, Tokyo, Japan
Objectives: Antimicrobial stewardship is important in the intensive care unit (ICU), where critically ill patients are managed. Herein, we aimed to evaluate the associations between the timing of antimicrobial stewardship team (AST) interventions in the ICU and patient mortality and to identify the optimal timing of interventions to improve patient survival.
Materials and methods: We retrospectively analyzed the data of patients admitted to the ICU at Showa Medical University Northern Yokohama Hospital (April 2016 – March 2023). The primary outcome was in-hospital mortality; the key exposure was the timing of AST intervention following antimicrobial initiation. Mortality incidence rates per 100 person-days and age-adjusted incidence rate ratios were calculated.
Results: Overall, 94 patients were included. Earlier AST intervention after ICU admission was associated with the lowest mortality (incidence rate (IR): 0.205 (95% confidence interval (CI): 0 – 0.512) per 100 person-days). In an age-adjusted analysis, later intervention was associated with a higher mortality incidence rate than earlier intervention (IR ratio (IRR): 5.53 (95% CI: 1.30 – 23.50), p = 0.02).
Conclusion: Earlier AST intervention after ICU admission was associated with lower mortality in ICU patients. Proactive and timely stewardship efforts are therefore needed in ICUs.Correspondence to:
Dr. Akitoshi Takuma
Department of Pharmacy
Showa Medical University Northern Yokohama Hospital
Chigasaki Chuo 35-1, Tsuzuki-ku,
Yokohama, Kanagawa 224-8503, Japan
Email: [email protected]

Abstract

International Journal of Clinical Pharmacology and Therapeutics, Vol. 64 – No. 9/2026 (482-486)

Prolonged cholinergic toxidrome with markedly low cholinesterase activity after exposure to emamectin benzoate emulsion: A case report 

Hideo Chubachi¹, Noritaka Kitazume¹, Kenji Momo², and Haruka Kamagata³

¹Department of Pharmacy, Shonan-Fujisawa Tokushukai Hospital, Fujisawa-shi, Kanagawa, ²Division of Clinical Research, Department of Hospital Pharmaceutics, School of Pharmacy, Showa Medical University, Hatanodai Shinagawa-ku, and ³Department of Emergency Medicine, Shonan-Fujisawa Tokushukai Hospital, Fujisawa-shi, Kanagawa, Japan
Emamectin benzoate emulsion is a macrocyclic lactone insecticide that is not classified as an organophosphate or carbamate. We report the case of a man in his 80s with chronic kidney disease and cardiovascular comorbidities who ingested emamectin benzoate emulsion. On day 2, he presented with abdominal pain, diarrhea, and marked sialorrhea; his vital signs were stable; however, his serum cholinesterase (ChE) had markedly declined (18 U/L). The patient was discharged with supportive care. From day 3, watery diarrhea recurred and neurobehavioral symptoms progressed. On day 5, he presented with pinhole miosis and further ChE suppression (2 U/L). Therefore, atropine was administered, and the patient was transferred for close monitoring. After discharge (day 8), miosis and sialorrhea persisted, and ChE remained low for weeks. Findings suggestive of tubular injury were observed during follow-up. The patients’ symptoms resolved gradually, with ChE partially recovering by days 75 – 95. This case underscores the need for serial reassessment and structured follow-up after pesticide exposure, even when the patient appears stable at the initial presentation.Correspondence to:
Hideo Chubachi, MD
Department of Pharmacy
Shonan-Fujisawa Tokushukai Hospital
Tsujido-Kandai 1-5-1, Fujisawa-shi,
Kanagawa 251-0041, Japan
or Associate Prof. Kenji Momo, PhD
Division of Clinical Research
Department of Hospital Pharmaceutics
School of Pharmacy, Showa Medical University
Hatanodai 1-5-8, Shinagawa-ku,
Tokyo 142-8555, Japan
Email: [email protected]; [email protected]

Warenkorb Übersicht
Typ	Anz	Rabatt	MwSt	Preis
Der Warenkorb ist leer

Ihr Warenkorb

Search Results

Warenkorb Übersicht

Senden Sie uns eine E-Mail